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Abstract:  The nociceptin/orphanin FQ (NOP) receptor is involved in a wide range of 
biological functions, including pain, anxiety, depression and drug abuse. Especially, its 
agonists have great potential to be developed into anxiolytics. In this work, both the   
ligand- and receptor-based three-dimensional quantitative structure–activity relationship 
(3D-QSAR) studies were carried out using comparative molecular field analysis (CoMFA) 
and comparative molecular similarity indices analysis (CoMSIA) techniques on 103   
N-substituted spiropiperidine analogues as NOP agonists. The resultant optimal   
ligand-based CoMSIA model exhibited Q
2 of 0.501, R
2
ncv of 0.912 and its predictive ability 
was validated by using an independent test set of 26 compounds which gave R
2
pred value of 
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0.818. In addition, docking analysis and molecular dynamics simulation (MD) were also 
applied to elucidate the probable binding modes of these agonists. Interpretation of the 3D 
contour maps, in the context of the topology of the active site of NOP, provided insight into 
the NOP-agonist interactions. The information obtained from this work can be used to 
accurately predict the binding affinity of related agonists and also facilitate the future 
rational design of novel agonists with improved activity. 
Keywords: NOP agonist; N-substituted spiropiperidine analogues; 3D-QSAR; molecular 
docking; molecular dynamics 
 
1. Introduction 
NOP, the nociceptin/orphanin peptide, is a 17-amino acid neuropeptide which was discovered in 
1995 [1,2]. Though structurally related to the opioid peptidedynorphin A [3,4], NOP lacks the   
N-terminal tyrosine necessary for activation of μ-, κ- and δ- opioid receptors and therefore does not 
bind to the opioid receptors. Actually, as an endogenous ligand, it binds only to its own receptor,  
i.e., the NOP receptor (also known as ORL1, OP4 or LC132) which was cloned in 1994 [5] and named 
after this ligand. NOP receptor belongs to the transmembrane G-protein coupled receptor family, and is 
widely distributed in the central nervous system with the highest density in the forebrain, brainstem, 
dorsal and ventral horns of the spinal cord. Besides, it is also present in the peripheral nervous system 
as well as in some non-neural tissues (epidermis, immunocytes, and vascular endothelium) [6–8]. Due 
to the therapeutic potential of the NOP receptor, it has received considerable attention in research since 
it was cloned. 
The agonists of NOP receptor have a broad therapeutic potential [9] to be used as antitussives, 
anxiolytics, vasodilators, hypotensives and in the treatment of neuropathic pain, drug dependence, 
urinary incontinence, congestive heart failure, and anorexia [10]. Thus scientists have spared no effort 
in development of NOP agonists, ending up with a variety of reported agonists. Generally, they can be 
divided into two classes: the peptide ligand and non-peptide ligand. For the first class of peptide ligand, 
the most typical one is the NOP which not only binds to, but also activates, the normal function of 
NOP receptor. In addition, some nociceptin-related peptides were also reported with high NOP binding 
affinities as NOP agonists [11–18]. As to the second class of non-peptide agonists, several groups of 
NOP ligands based on structural differences have been discovered, including piperidines, nortropanes, 
spiropiperidines, 4-amino-quinolines and quinazolines, and others [10]. Among these, the most 
extensively studied is the triazaspirodecanone Ro 64-6198 synthesized by Roche group [19], which has 
indeed become a valuable pharmacological tool in determining the potential of the NOP receptor as a 
therapeutic target. Based on this triazaspirodecanone, a series of spiropiperidines were further 
synthesized by optimization of a high-throughput screening lead containing the triazaspirodecanone 
(comprising the A and B moieties of the proposed pharmacophore) and a substituted 2-tetralinyl 
moiety as the lipophilic C moiety directly linked to the basic piperidine nitrogen [20]. Intracerebral 
infusions of NOP or systemic injections of the NOP receptor agonist, Ro64-6198, were found to affect 
neuroendocrine function, feeding, locomotion, learning and memory, anxiety, stress response and Int. J. Mol. Sci. 2011, 12 
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sexual behavior [21–28]. Due to the therapeutical potential of spiropiperidines, a series of   
N-substituted analogs based on the spiropiperidine analogues were synthesized by Caldwell JP, which 
exhibited high binding affinity to the NOP receptor [29,30]. 
The comparative molecular field analysis (CoMFA) method proposed in 1988 by Crammer et al. 
and the subsequently developed comparative molecular similarity indices analysis (CoMSIA) method 
have been extensively used in many present practices of drug discovery and development as   
three-dimensional quantitative structure-activity relationship (3D-QSAR) approaches [31–37], due to 
their outstanding advantages of time-saving, cost-reducing as well as the highly efficient in silico 
screening and prediction of candidate drugs. Until now, in silico studies on spiropiperidine analogues 
as agonists of NOP receptors are still very limited, especially 3D-QSAR studies. Therefore, a   
3D-QSAR analysis on this kind of NOP ligands should be of great significance. 
In the present work, a total of 103 N-substituted spiropiperidine analogues were computationally 
studied to build 3D-QSAR models using CoMFA and CoMSIA methodologies [38]. The predictive 
abilities of the obtained models were validated statistically by an independent test set of compounds. 
Furthermore, a combined in silico approach including docking analysis, and molecular dynamics (MD) 
simulation was also employed to elucidate the probable binding modes of these agonists at the active 
site of the NOP receptor. We hope this study will support the use of spiropiperidine analogues as a 
potential therapeutic agent by targeting NOP and be helpful in designing novel and more effective 
NOP agonists as desired. 
2. Results and Discussion 
2.1. CoMFA and CoMSIA Statistical Results 
Since the alignment of compound structures plays an important role in developing successful   
3D-QSAR models [39], two rules (both ligand-based and docking-based) were adopted to align the 
dataset to derive reliable models. The results obtained from both models using the same training   
set of 81 compounds are summarized in Table 1. A number of statistical parameters, i.e., the Q
2,  
non-cross-validated correlation coefficient (R
2
ncv), SEE, and F-statistic values, are analyzed to evaluate 
the quality of the models. 
In both CoMFA and CoMSIA analyses, ligand-based alignment modeling leads to models with 
larger R
2
cv, R
2
ncv, R
2
pred values than the corresponding models obtained by the receptor-based alignment 
modeling. Therefore, we mainly focussed on the ligand-based 3D-QSAR models for further analysis. 
In addition, since the five (steric, electrostatic, hydrophobic, and H-bond donor and acceptor) field 
descriptors may not be completely independent of each other and such dependency among individual 
fields may reduce the model significance and generalization [40,41], all possible combinations of the 
descriptors were used to derive models for avoiding the risk of omitting possible optimal model and to 
explore the best combination use of the descriptors for model generation. Finally, a CoMSIA model 
established by using the steric, electrostatic, hydrophobic and hydrogen bond donor field descriptors 
appears to be superior to all other models derived, whose statistical results are listed in Table 1. Using 
seven PLS components, this model yields statistical results of Q
2 = 0.501, R
2
ncv = 0.912, SEE = 0.250 
and F = 108.309 with steric (12.4%), electrostatic (38.7%), hydrophobic (24.4%) and H-bond donor 
(24.5%) field contributions, proving its correct internal predictive capability. Int. J. Mol. Sci. 2011, 12 
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Table 1. Summary of CoMFA and CoMSIA results. 
PLS Statistics 
Ligand-Based Model  Receptor-Based Model 
CoMFA  CoMSIA  CoMFA  CoMSIA 
Q
2  0.229  0.503  0.047  0.111 
R
2
ncv  0.621  0.921  0.196  0.527 
SEE  0.507  0.237  0.728  0.559 
F  41.472  120.623  19.064  86.880 
R
2
pred  0.712  0.788  0.227  0.385 
SEP  0.723  0.596  0.793  0.766 
PLS components  3  7  1  1 
Contribution   
Steric  0.528  0.122  0.435  0.172 
Electrostatic  0.472  0.355  0.565  0.242 
Hydrophobic    0.258    0.249 
H-bond donor    0.266    0.337 
Q
2: Leave-one-out cross-validated correlation coefficient; R
2
ncv: non-cross-validated correlation coefficient; 
SEE: standard error of estimate; F: ratio of R
2
ncv explained to unexplained R
2
ncv/(1 − R
2
ncv); R
2
pred: predicted 
correlation coefficient for the test set of compounds; SEP: standard error of prediction; PLS components: the 
optimal number of principal components. 
Generally speaking, a Q
2 > 0.5 is considered proof of acceptable internal predictive ability [42]. 
What’s more, the high R
2
ncv and F values along with the low SEE values should also be considered as 
the foundation of a reliable QSAR model [43]. However, due to chance correlation or structural 
redundancy, sometimes it is found that some models derived from the training set molecules with 
randomized activity possess high Q
2 values, but show unfavorable predictivity for prediction of 
unknown molecules [33,44]. Hence, the extensively accepted leave-one-out (LOO) cross-validated Q
2 
is insufficient to assess the predictive power of the QSAR models [45]. In light of such risks, we 
validated the models by predicting the activity of an external test set composed of 22 NOP agonists. As 
a result, a predictive coefficient R
2
pred of 0.818 was achieved verifying the good external predictive 
efficacy of the model (Table 1). Figure 1 illustrates the correlation plot of experimental versus 
predicted pKi values of the training (filled red square) and test (filled green triangle) sets based on the 
optimal CoMSIA model. Clearly, a good correlationship is observed from this figure since the 
predicted values are almost as accurate as the experimental activities for the whole dataset, and all 
points are rather uniformly distributed around the regression line, indicating no existence of systematic 
errors in the method. This good agreement between the predicted and experimental activity data proves 
the satisfactory predictive ability of the CoMSIA model. 
  Int. J. Mol. Sci. 2011, 12 
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Figure 1. The correlation plots of predicted versus actual pKi values using the training 
(filled red squares) and test (filled green triangles) sets based on the optimal CoMSIA 
model. The solid lines are the regression lines for the fitted and predicted bioactivities of 
training and test compounds, respectively. 
 
2.2. 3D-QSAR Contour Maps 
The 3D-coefficient contour plots are beneficial to identify important regions where some changes in 
the interaction fields can affect the biological activity, and may also be of help to identify the possible 
interaction sites of the biochemical system. Thus presently, the optimal ligand-based CoMSIA model 
is selected for each conformation to construct the stdev*coeff contour maps to view the field effects on 
the target features due to its good internal and external predictive powers. The maps generated depict 
regions having scaled coefficients greater than 80% (favored) or less than 20% (disfavored). To aid in 
visualization, the most active compound 32 is shown as template molecule with the contour maps (Figure 2). 
The CoMSIA steric contour plot for the most active compound 32 is displayed in Figure 2A, where 
the sterically favored regions are shown in green and disfavored regions in yellow, respectively. As 
seen from this picture, some green contours are mapped near position-1 of ring A, positions-11 and -12 
of ring D and positions-19 and -20 of ring E, suggesting that bulkier groups are favored at these 
positions. The green contour around position-1 is well consistent with the higher potency of compound 53 
with a bulkier substituent (CH3OC(O)CH2-) (pKi = 7.71) than compound 15 without substituent   
(pKi = 7.63) at position-1 of ring A. The higher potency of compound 38 (pKi = 8.85, with a CH3 group) 
than 36 (pKi = 7.96, without substituent) is also such a case. A few residues located around positions-11, 
-12, -19 and -20 lead to a large empty space at these positions (as shown in Section 2.3), which can 
interpret the presence of green contours at these positions. Two yellow contour maps appeared above 
ring C and between ring C and ring D, respectively, implying that bulkier substituents at these Int. J. Mol. Sci. 2011, 12 
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positions may decrease the activity; the reason may be that there is no such bulky substituent at these 
positions of both rings C and D in all molecules of the dataset. 
Figure 2. CoMSIA stdev*coeff contour plots for NOP in combination with compound 32. 
(A) Steric (green/yellow) contour map. Green contours indicate regions where bulky 
groups increase activity; yellow contours indicate regions where bulky groups decrease 
activity; (B) Electrostatic contour map (blue/red). Blue contours indicate regions where 
positive charges increase activity; red contours indicate regions where negative charges 
increase activity; (C) Hydrophobic contour map (yellow/white). Yellow contours indicate 
regions where hydrophobic substituents enhance activity; white contours indicate regions 
where hydrophobic substituents decrease activity; (D) CoMSIA contour maps illustrating 
hydrogen-bond donor features. The cyan contour represents the H-bond donor favored 
region, purple indicates the disfavored region. 
 
Figure 2B depicts the electrostatic contour maps obtained from the CoMSIA model, where blue 
contours represent the favorable electropositive regions and red contours account for the favorable 
electronegative regions, respectively. A large blue contour extending from position-1 to position-4 
indicates that electropositive groups are preferred here. Compound 62 with substituent of 
(CH3)2N(CH2)2- at position-1 shows higher activity than compound 56 with substituent of NH2(CH2)2- 
due to the stronger electronegativity of the former substituent. Besides the large blue contour, a red 
contour can be seen near position-1 of ring A indicating that this position is sensitive to electrostatic 
substituents. This phenomenon may have something to do with the atom N (electronegative atom) of 
ligand 32 at position-1. In addition, the atom O (electronegative atom) of ligand 32 at position-5, may 
be the reason for the small red contour showing around here. The function and location (next to Int. J. Mol. Sci. 2011, 12 
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position-1) of atom O at position-5 may lead to the red contour appearing around position-1. Also a 
blue contour located at positions-11 of ring D, suggests the possible help of electropositive substituents, 
improving the binding affinity. Actually, this may be due to the existence of the electro-negative 
amino acids Asp130 and Asp209 in the binding pocket, as discussed later in Section 2.3, because of 
the lack of any substituents in these areas. In addition, a large red contour map is seen around position-8, 
which is caused by the electronegative atom N and an electro-positive amino acid Arg302   
(as discussed later in Section 2.3). 
Figure 2C shows the CoMSIA hydrophobic contour map, where the yellow (hydrophobic favorable) 
and white (hydrophobic unfavorable) contours represent 80% and 20% contributions respectively. 
Substitutions by hydrophobic groups like -Cl and -F at positions-18 and -19 are extended to the yellow 
contours resulting in a higher NOP activity, which can be illustrated by the example that compound 33 
with -F at position-18, and compound 32 with -F at position-19 all exhibit higher activities than 
compound 29 without any substituent at either positions-18 or -19, respectively. The existence of atom F at 
position-19 may be the reason for the yellow contour extending. Furthermore, two large yellow regions 
are observed above positions-6 and -7 and around position-9 of ring C, respectively. Also some white 
regions are observed close to position-1 of ring A, ring B, positions-11 and -12 of ring C and position-17 of 
ring E indicating that hydrophilic groups here are helpful for the activity. The fact that compound 83 
with hydrophilic group -(CH2)2OH has higher potency than compound 103 with hydrophobic group  
-NHBu at position-1 verifies this conclusion. What’s more, compound 54 with hydrophilic   
substituent-(CH2)2OH at position-1 shows higher binding affinity than both compounds 51 (with 
hydrophobic group -Bu) and 52 (with hydrophobic group i-Amyl-). The white contour around 
positions-11 and -12 of ring C and position-17 of ring E may be attributed to the existence of the 
hydrophilic residues (Asp110, Asp209, Asp130, Thr103, Thr305, Tyr309, Gln107 and Arg302) in 
binding pocket, as discussed later in Section 2.3 and shown in Figure 3B. 
In Figure 2D, the CoMSIA hydrogen-bond donor plot, the cyan contours indicate regions where 
hydrogen bond donor substituents on the ligands are favored and the purple contours represent areas 
where hydrogen bond donor substituents on agonists are disfavored. As seen from the picture, a large 
cyan contour appears around position-1. Its appearance was due to the atom N at position-1 acting as 
an H-bond donor and interacts with the key amino residues around the position (as discussed later in 
Section 2.3). The only structural difference of compounds 72~79, lies in the substituent at position-1 
(such as the EtNHCH2CH2- and BuNHCH2CH2- groups) which can serve as the H-bond donor for 
interaction with the surrounding environment. Thus, they all exhibit higher pKi values than compound 80 
with H-bond accepter substituent (
Cl
) at position-1, providing powerful proof for the 
conclusion. The atom N and atom O located at position-1 and position-5 respectively, both of which 
can act as H-bond donors, may be the reason for the large purple area around these positions. 
2.3. Docking Studies 
Due to the important role in the rational design of a drug, docking is often used to find the optimal 
orientation of a ligand in the binding to its pharmaceutical target [46]. In our work, the whole dataset 
of 103 compounds were docked into the possible active site of NOP receptor crystal structures, and the 
optimal conformations of these compounds were determined. The results show that all molecules in Int. J. Mol. Sci. 2011, 12 
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the series were well placed in the active site demonstrating the rationality and reliability of the docking 
model. The binding mode of the highly potent compound 32 docked into the receptors is taken as an 
example and shown in Figure 3. As observed from this figure, the ligand core is anchored in the 
binding site via  hydrophobic interactions and two H-bonds are identified as potential factors 
influencing the high binding affinity of compound 32. The specific binding interactions are analyzed in 
detail as follows. 
Figure 3. The binding site formed around compound 32. (A) Interactions with the key 
amino acids in the binding pocket. The dashed lines show the formation and distance (in Å) 
of the hydrogen bonds. Active site amino acid residues are represented as lines, the agonist 
is shown as stick model, respectively; (B) The pink cylinders represent the polar residues, 
where, especially the ones with red circles, represent the acid residues and the one with a 
blue circle represents basic residue. The green cylinders represent non-polar residues. Dash 
lines represent the H-bond interactions. 
 Int. J. Mol. Sci. 2011, 12 
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As seen from the picture, compound 32 is actually docked into a basically hydrophobic pocket 
which is formed by Trp116, Trp211, Trp276, Val126, Pro207, Phe106, Phe220, Ile127, and Phe106. 
This finding reaches good agreement with the previous CoMSIA hydrophobic contour maps analysis 
in Figure 2C, that most hydrophobic residues around the binding ligand are consistent with those 
yellow contours appearing around position-9 of ring C and positions-18 and -19 of ring E. In addition, 
the presence of several hydrophilic residues (Asp209, Asp130, Thr103, Thr305, Tyr309 and Arg302) at 
positions-1, -11, -12 and -17 also conforms well with the white contours in Figure 2C. 
In addition, altogether two H-bonds are observed in Figure 3 playing crucial roles in anchoring the 
ligand in the binding site. The -NH- of ring A as the hydrogen bond donor forms an H-bond with 
Thr103 with a distance of 2.28 Å. This observation correlates well with the cyan contour located 
around position-1 (representing the H-bond favored region) in previous CoMSIA hydrogen bond 
donor contour maps (Figure 2D). Besides this, another H-bond is also observed in the docking pocket,  
the one between the F atom at position-19 and Tyr309 (3.37 Å), which acts as a supplement for the 
contour map. 
Our docked model also shows a comparatively large empty space around positions-11 and -12 of 
ring D and positions-19 and -20 of ring E, indicating that in these regions the steric interaction may be 
favorable. The conclusions are similar to the previous CoMSIA contour maps in Figure 2A that large 
blue contours show around positions-11 and -12 of ring D and positions-19 and -20 of ring E, 
respectively. From Figure 3A, we can see many key amino acid residues around rings C and D, which 
correlates well with the two yellow contours as shown in Figure 2A. Quite a lot of residues appear 
around position-1 creating no empty space, in contrast to the result obtained from the analysis of 
CoMSIA steric contour maps. The fact that position-1 plays a key role in CoMSIA field analysis 
(discussed in Section 2.2) may account for the difference, which in turn leads to its interaction with 
many residues (Trp116, Thr103, Val126 and Phe106). Several residues are also observed around rings 
B and C, giving supplement for the steric interactions around them, which indicates that bulky 
substituents around rings B and C should be harmful to the increase of binding affinity. 
All in all, the docking results and the 3D contour maps complement and validate each other, 
indicating that the QSAR models generated in the present study are reasonable and could be used to 
derive useful information in the future rational design of NOP agonists. 
2.4. Molecular Dynamics Simulations 
Since our molecular docking process does not take the protein flexibility into consideration, 
presently 5 ns molecular dynamics simulations of NOP receptor with ligand 32 were carried out on the 
basis of the docked complex structure for the purpose of “drawing” a dynamic picture of the 
conformational changes in the NOP receptor binding site. 
The RMSDs (root-mean-square deviation) of the trajectory in regard to the initial structure ranging 
from 2.5 to 4.5 Å are presented in Figure 4A. As a result, after 2500 ps the RMSD of the complex 
attains about 4.0 Å and almost remains this value for the whole process. This clearly indicates 20 
metastable conformations after 2500 ps of simulation for the docked complex structure. Figure 4B 
depicts a superposition of the average structure for the last 1 ns and the docked structure. The right 
hand side picture of Figure 4B is an enlarged view of the superposition of an average structure for the 
last 1 ns, and the docked structure of ligand 32, where the cyan stick represents the initial structure of Int. J. Mol. Sci. 2011, 12 
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the docked complex and the green stick represents the MD-simulated structure, respectively. Ligand 32 
is shown in blue for the initial complex and, separately, in green for the final average complex. 
Obviously, there are no significant changes in both the protein and ligand 32 superpositions between 
the docked structure and the average structure obtained from MD simulations, which verifies the 
reasonability of the docking model. 
Figure 4. MD simulation results: (A) Plot of the root-mean-square deviation RMSD of 
docked complex versus the MD simulation time in the MD-simulated structures; (B) 
Structural superposition of the MD simulation and the initial structure for NOP receptor. 
The projection highlights the superimposed backbone atoms of the average structure of the 
last 1 ns of the MD simulation (green) and the initial structure (cyan) for compound 32 
with NOP complex. 
 
3. Discussion 
The development of nociceptin/orphain FQ receptor agonists has been a hot topic in research fields 
for a long time. However, until now the in silico study on N-substituted spiropiperidine-based NOP 
agonists is seldomly reported except for the work of Luo HB et al. in 2010, where a dataset composed 
of 67 spiropiperidine analogues was investigated using the CoMFA approach [47]. By comparing the 
results of their work with ours, both similarities and differences exist, including the quantitative 
change of the number of molecules used in the dataset (67 in theirs, which is actually a subset of our 
dataset composed of 103 NOP agonists). 
In detail, both theirs and our skeletons of the molecules consist of heterocyclic ring A with 
variations of substituents at position-1, benzene ring B and heterocyclic ring C with variations of 
substituents at position-3. In activity (pKi), their activity ranges from 0.4 to 234 nM while ours varies 
from 0.3 to 824 nM, respectively. Although both theirs and our work adopts the molecular docking Int. J. Mol. Sci. 2011, 12 
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method, they only docked their highly potent molecular P67 while we docked the whole dataset of 103 
compounds into the binding pocket of the target. Furthermore, based on the molecular dynamics 
analysis we carried out, the interaction features of these spiropiperidine analogues with the NOP 
receptor were further investigated and validated. Figure 5 summarizes the binding modes of each work, 
where the similarities and differences of the two papers are easily observed. 
Figure 5. Comparison of the interaction features of (A) ligand 32 and (B) compound P67 [47] 
with NOP receptor. 
 
Figure 5A displays the key structural features impacting the activity obtained from our present work 
and Figure 5B displays the features obtained by Luo et al., respectively. The most active NOP agonist 
in each respective dataset, i.e., ligand 32 in ours and compound P67 in Luo’s dataset is shown as  
a template in Figure 5A and B respectively. In Figure 5, green dash lines represent H-bond interaction 
regions and other curved lines represent the specific interaction regions. Int. J. Mol. Sci. 2011, 12 
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As seen from the figure, the two works draw two similar conclusions that: (i) areas around position-1 of 
ring A are electrostatic-sensitive, which have both electropositive and electronegative favored regions; 
(ii) Area around ring D is the bulky electropositive favored region. 
Despite the above similarity, the difference in structural features of the two works is also distinct:  
(i) the interactions and main amino acid residues around the atom N of ring A are different. The reason 
might be that compound P67 (in Figure 5B) has a substituent of an electropositive group   
(i-AmylNH(CH2)2-) at the position, which affects the interactions between compound P67 and relevant 
residues greatly; (ii) A minor electronegative hydrophobic favored region is observed around ring C 
for compound 32 while it does not exist for compound P67. The reason is that our results are based on 
the optimal CoMSIA model derived by using of steric, electrostatic, hydrophobic and hydrogen-bond 
donor field descriptors while Luo’s results were obtained from a CoMFA model with only the steric 
and electrostatic field descriptors employed; (iii) The size of the binding spaces for the two datasets are 
different, due to the fact that compound 32 is surrounded by more amino residues (Asp130, Thr305, 
Ile127 and Pro207) than compound P67 [48,49]; (iv) The interactions around ring E are different for 
the two compounds. Compound P67 has a minor electronegative favored region around ring E while 
compound 32 has a bulky hydrophobic favored region around ring E, which may be due to the fact that 
compound P67 has two polar residues Asp290 and Tyr 210 surrounding this region in the pocket, while 
compound 32 is surrounded by some non-polar residues such as Phe220, Trp211 and Trp276; (v) As 
for the H-bonds, ligand 32 forms two H-bonds, while compound P67 produces three. The two H-bonds 
of ligand 32 are explained in Section 2.3. The three H-bonds of compound P67 are formed by atom N 
at the substituent of ring A with related key amino residues, one is formed with Asp110 and the other 
two are formed with Arg302. The difference in both the molecular structure and the surrounding amino 
residues of ligands 32 and P67 leads to the different H-bond interactions. All in all, these conclusions 
would help guide the further development of N-substituted spiropiperidine-based NOP agonists with 
improved potency. 
4. Materials and Methods 
4.1. Database and Biological Activity 
Discarding those compounds with unspecified agonistic activity and/or with undefined 
stereochemistry, a total of 103 spiropiperidines analogues with a wide spectrum of activities against 
the nociceptin/orphanin FQ receptor synthesized by Caldwell JP et al. were used as the dataset for 
molecular modeling in this study [29,30]. In vitro biological activities were converted into 
corresponding pKi (-lgKi) values and used as dependent variables in the QSAR analysis.   
In approximately a ratio of 4:1, all molecules was divided into training (81 compounds) and test (22) 
sets. The selection of the test set chemicals obeys the rule that their pKi values are randomly but 
uniformly distributed in the range of the values for the whole set so that the model’s predictive power 
could be effectively evaluated. Table 2 shows the representative skeletons and activities of the 
molecules, with all structures and binding affinity values of the dataset listed in supporting   
information Tables S1–S3. 
During the modeling process, the 3D structures of all compounds were subjected to full geometry 
optimization using the sketch molecule module of Sybyl 6.9 package [50]. Partial atomic charges were Int. J. Mol. Sci. 2011, 12 
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calculated by the Gasteiger-Huckel method [51], and energy minimizations were performed by using 
the Tripos force field [52] and the Powell conjugate gradient algorithm with a convergence criterion of 
0.05 kcal/mol. 
Table 2.  Representative skeleton, molecular structure and binding affinity (Ki, nM) of 
spiropiperidine analogues. 
N
N
N
R
O
R1  
No.  R  R1
  Ki  No.  R  R1
  Ki 
5  H  824.0  44 
#  Bu 
 
57 
6
  H  H
S  
14.0  47  c-BuCH2- 
 
53 
11  H 
 
2.4  54 
#  HO(CH2)2- 
Cl Cl
 
18.5
16  H 
 
225.0  69  N ( CH2 )3 一
 
Cl Cl
 
3.2
19  H 
Cl
 
9.0  75
  c-BuNH(CH2)2- 
Cl
Cl  
0.5
26 
#  H 
F F
 
250.0  79  Et2N(CH2)2- 
Cl
Cl  
1.0
30  H  14.5  87  c-Pentyl NH(CH2)2- 
 
0.9
32  H 
F
0.3  90 
#  CH2=CHCH2NH(CH2)2- 
 
0.9
36 
#  H 
Cl
 
10.8  97  i-AmylNH(CH2)2- 
 
0.4
39 
#  H 
F 8.4  103  BuNH(CH2)2- 
Cl
Cl
 
12.2
# Molecules belonging to the test set. 
4.2. Conformational Sampling and Alignment 
Molecular alignment of compounds is a crucial step in the development of 3D-QSAR models [44]. 
In order to obtain the best possible 3D-QSAR statistical model, two different alignment rules were 
adopted. The first rule is the ligand-based alignment. During the process, the most potent molecule 
(compound 32) was chosen as a template to fit the remaining training and test sets of compounds by 
using substructure-alignment function available in Sybyl. The common substructure for the alignment 
is described in Figure 6A, and the resulting ligand-based alignment model is shown in Figure 6B. The 
alignment result based on another rule, the receptor-based one, is shown in Figure 6C. 
H
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Figure 6. Molecular alignment of compounds in the dataset. (A) Common substructure of 
the molecules is shown in bold based on template compound 32; (B) Ligand-based 
alignment of all the compounds; (C) Receptor-based alignment of all the compounds. 
 
4.3. CoMFA and CoMSIA Field Calculation 
The CoMFA and CoMSIA models were generated by using Sybyl 6.9 with the default parameters. 
Detailed algorithms of CoMFA and CoMSIA can be easily referred to many literatures, thus we only 
introduce the modeling parameters in this work. 
To derive the CoMFA and CoMSIA descriptor fields, a 3D cubic lattice with grid spacing of 2 Ǻ in 
x, y, and z directions, was generated automatically to encompass the aligned molecules. In CoMFA, the 
steric and electrostatic fields were calculated separately for each molecule using sp
3 carbon atom probe 
with a charge of +1.00 and energy cut-off values of 30 kcal/mol for both the steric and electrostatic 
fields. The probe atom was placed at each lattice point, and its steric and electrostatic interactions with 
each atom in the molecule were computed using the CoMFA standard scaling. 
CoMSIA similarity index descriptors were derived using the same lattice boxes as those used in 
CoMFA calculations. In CoMSIA, the steric, electrostatic, hydrophobic, and hydrogen-bond (H-bond) 
donor and acceptor descriptors were calculated using a probe atom of radius 1.0 Ǻ, charge +1.0, and 
hydrophobicity +1.0. A Gaussian function is used to evaluate the mutual distance between the probe 
atom and each molecule atom. Because of the different shape of the Gaussian function, CoMSIA 
similarity indices (AF) for molecule j with atom i at grid point q are calculated by equation: 

2
, k ,
iq e j A ik k probe
q
F
  
      (1)
where k represents the steric, electrostatic, hydrophobic, or hydrogen-bond donor or acceptor descriptor. 
ωprobe,k is the probe atom with radius 1.0 Ǻ, charge +1, hydrophobicity +1, H-bond donating +1,   Int. J. Mol. Sci. 2011, 12 
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H-bond accepting +1; ωik is the actual value of the physicochemical property k of atom i; γiq is the 
mutual distance between the probe atom at grid point q and atom i of the test molecule. The 
attenuation factor was set to 0.3. 
4.4. 3D-QSAR Model Generation 
In order to generate statistically significant 3D-QSAR models, partial least squares (PLS) 
regression was adopted to analyze the training set by correlating the variation in their pKi values  
(the dependent variable) with variations in their CoMFA/CoMSIA interaction fields (the independent 
variables). PLS is a statistical approach that generalizes and combines features from principal 
component analysis and multiple regressions. When the matrix of predictors has more variables than 
observations (multicollinearity), PLS is particularly a useful way to predict a set of dependent variables 
from a large set of independent variables. 
Leave-one-out (LOO) cross-validation analysis that one compound was moved away from the 
dataset and its activity was predicted by the model derived from the rest of the dataset, was performed 
to evaluate the reliability of the models generated from the PLS analysis. A cross-validated correlation 
coefficient, Q
2, was subsequently obtained and provided as a statistical index of the predictive power. 
Then, a non-cross-validation analysis was carried out with the Pearson coefficient (R
2
ncv) and standard 
error of estimate (SEE) calculated. Finally, the CoMFA/CoMSIA results were graphically represented 
by field contour maps, where the coefficients were generated using the field type “Stdev*Coeff”. 
In order to evaluate the real predictive ability of the best models generated by the CoMFA/CoMSIA 
analyses using the training set, the 26 compounds not used in the model generation are used as the 
external validation set. A predictive R value was then obtained with the following formula: 
-
pred
SD PRESS
SD R 
 
(2)
where SD denotes the sum of squared deviation between the biological activities of the test set 
molecule and the mean activity of the training set molecules; PRESS represents the sum of squared 
deviations between the experimental and predicted activities of the test molecules, respectively. 
4.5. Molecular Docking 
Molecular docking was carried out by the Surflex-dock module (V 2.51) [53] of an advanced 
version of Sybyl-X 1.1 [54] to understand the detailed binding model for the active site of NOP 
receptor with its ligands. In Surflex-docking, protomol was a computational representation of the 
intended binding site to which putative ligands were aligned and its construction was based on the 
protein residues proximal to the native ligand and on parameter settings to produce a small and buried 
docking target. Up to now, the protein structure has not been resoluted and the identities of our 
homology modeling models are below 30%. However, Luo HB from School of Pharmaceutical 
Sciences, Sun Yat-Sen University, who has done the similar studies on NOP receptor and used 
homology modeling to make a protein, is very kind to provide us his protein structure for our study. 
The molecular docking process is summarized as the following steps: First, the template protein 
structure was imported into Surflex. Then the protomol was generated using a ligand approach. Two Int. J. Mol. Sci. 2011, 12 
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parameters, protomol_bloat and protomol_threshold, which respectively determine how far from a 
potential ligand the site should extend and how deep into the protein the atomic probes used to define 
the protomol can penetrate, are set at 0 and 0.60 respectively. Finally, each conformer of all 103 
agonists was docked into the binding site 20 times. The Hammerhead scoring function [55] is used to 
score the molecules in the putative poses. During the present molecular docking process, the protein 
was considered to be rigid, and the ligand molecules were flexible. All other parameters were setting at 
default values. 
4.6. Molecular Dynamics Simulations 
After docking analysis, the docked structure of compound 32 was applied in the MD simulations 
using the Amber 10 [56]. The general atom force field (GAFF) [57] and the standard AMBER force 
field for bioorganic systems (ff03) [58] were used to model the ligand and protein respectively.   
The docked structure was neutralized with 9 counter chloridion ions and solvated in a rectangular box 
of TIP3P [59] water, which kept a minimum distance of 12 Å between the solute and each face of the 
box (74.984 × 97.951 × 67.771 Å
3). The total number of the atoms of the simulation system was  
40091 including the complex and waters. The cutoff distance was kept to 10 Å to compute the   
non-bonded interactions. All simulations were performed under periodic boundary conditions. To 
remove possible bad contacts, the complex was energy minimized by a multistep procedure including 
9500 conjugate-gradient steps followed by 500 steepest-descent steps. Constant volume dynamics with 
a cutoff of 10 Å was chosen. SHAKE [60] was turned on for bonds involving H-atoms. 
In the simulation process, first, the minimized system was heat up to 300 K at a constant rate of  
6 K/ps while the protein atoms were constrained. The second step depended on a 50 ps   
pressure-constant period to raise the density and keep the complex atoms constrained. The third step 
was a 500 ps Langevin dynamics calculation with a collision frequency of 1 ps
−1, which was performed 
with a 2 fs time step at a constant temperature of 300 K. Finally, the production phase was run for 5 ns 
with a 2 fs time step. The long-range electrostatics was treated by using the particle-mesh-Ewald (PME) 
method [61] with default values. 
5. Conclusion 
In this paper, the ligand- and receptor-based 3D-QSAR studies of 107 spiropiperidines analogues as 
agonists of nociceptin/orphanin FQ receptor have been performed using CoMFA and CoMSIA tools. 
From the resultant model, the high Q
2,  R
2
ncv, and R
2
pred values prove that the 3D-QSAR models 
developed in this work are statistically reliable and predictable. The resulting contour maps produced 
by the best CoMSIA model provide useful information about the intermolecular interactions of 
agonists with the surrounding environment. The good consistency between the 3D-QSAR, the docking 
and MD modeling results, once again, demonstrates the reliability of the model. The newly obtained 
3D model of NOP may serve as a basis for development of novel agonists with enhanced affinity. 
Overall, the conclusions are summarized as follows (with compound 32 as a reference): 
(1) Substituents with bulky, electro-sensitive, hydrophilic, H-bond donor at position-1, bulky 
hydrophilic substituents at positions-11 and -12 and minor hydrophobic substituents at 
positions-6, -7 and -9 of ring C may be helpful to enhance potency. Electronegative   Int. J. Mol. Sci. 2011, 12 
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H-bond acceptor at position-5, bulky hydrophobic substituents at position-19, bulky 
substituents at position-20, electropositive substituents at positions-4 and -11, electronegative 
substituents at position-8 and hydrophilic substituents at position-17 and ring B can all enhance 
the activity. 
(2) The binding site of N-substituted spiropiperidine-based NOP agonists is mostly a large 
hydrophobic pocket formed by Trp116, Trp211, Trp276, Val126, Phe220, Phe106, Ile127 and 
Pro207 residues. The H-bonds formed by polar residues Thr103 and Tyr309 can be identified 
as potential factors greatly impacting the binding affinity of compound 32. 
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